{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:43:55Z","timestamp":1791297835841,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.amjopharm.2010.08.006","type":"journal-article","created":{"date-parts":[[2010,9,25]],"date-time":"2010-09-25T08:43:58Z","timestamp":1285404238000},"page":"331-373","source":"Crossref","is-referenced-by-count":120,"title":["Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders"],"prefix":"10.1016","volume":"8","author":[{"given":"David R.P.","family":"Guay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2010.08.006_bib1","first-page":"7","article-title":"Tetrabenazine (Xenazine) for Huntington's chorea","volume":"51","year":"2009","journal-title":"Med Lett Drugs Ther"},{"issue":"Suppl 170","key":"10.1016\/j.amjopharm.2010.08.006_bib2","first-page":"1","article-title":"Tetrabenazine (Nitoman) in the treatment of psychoses. With a discussion on the central mode of action of tetrabenazine and reserpine","volume":"39","author":"Lingjaerde","year":"1963","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib3","series-title":"Tetrabenazine (Xenazine tablets) [package insert]","year":"2008"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0074-7742(08)60024-0","article-title":"Benzoquinolizine derivatives: A new class of monoamine decreasing drugs with psychotropic action","volume":"4","author":"Pletscher","year":"1962","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/0006-2952(89)90082-8","article-title":"Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles","volume":"38","author":"Henry","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib6","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1074\/jbc.271.6.2979","article-title":"Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine","volume":"271","author":"Peter","year":"1996","journal-title":"JBiol Chem"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0169-328X(94)90050-7","article-title":"Synaptic vesicular monoamine transporter expression: Distribution and pharmacologic profile","volume":"22","author":"Gonzalez","year":"1994","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(74)92338-1","article-title":"A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea","volume":"1","author":"McLellan","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0028-3908(88)90080-9","article-title":"Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease","volume":"27","author":"Pearson","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib10","first-page":"47","article-title":"Experimentelle Untersuchungen zur Pharmakologie des mit 3H-markierten tetra-benazines","volume":"11","author":"Stumpf","year":"1961","journal-title":"Arzneim Forsch"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib11","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/j.1471-4159.1993.tb03521.x","article-title":"In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography","volume":"60","author":"Kilbourn","year":"1993","journal-title":"J Neurochem"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib12","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. New Drug Application No. 21-894: Tetrabenazine. Medical and Clinical Pharmacology reviews."},{"key":"10.1016\/j.amjopharm.2010.08.006_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(25)06690-5","article-title":"Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies","volume":"15","author":"Mehvar","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/BF00615962","article-title":"The pharmacokinetics of tetrabenazine and its hydroxyl metabolite in patients treated for involuntary movement disorders","volume":"29","author":"Roberts","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0006-2952(66)90031-1","article-title":"Metabolic studies of tetrabenazine, a psychotropic drug in animals and man","volume":"15","author":"Schwartz","year":"1966","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1520-636X(1997)9:1<59::AID-CHIR11>3.0.CO;2-P","article-title":"Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine","volume":"9","author":"Kilbourn","year":"1997","journal-title":"Chirality"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0024-3205(83)90408-3","article-title":"Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine","volume":"33","author":"Reches","year":"1983","journal-title":"Life Sci"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00421263","article-title":"Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine","volume":"42","author":"Furukawa","year":"1975","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2007.07.010","article-title":"Neurotransmitter depleter tetrabenazine; potential candidate for schizophrenia treatment?","volume":"96","author":"Malik","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jama.1972.03190360051027","article-title":"Reversal of hemiballismus by tetrabenazine","volume":"219","author":"Pearce","year":"1972","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib21","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/mds.870030111","article-title":"Hemiballism in multiple sclerosis","volume":"3","author":"Riley","year":"1988","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00002826-198506000-00009","article-title":"Coprolalia associated with hemiballismus: Response to tetrabenazine","volume":"8","author":"Mart\u00ed-Mass\u00f3","year":"1985","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib23","first-page":"123","article-title":"Hemiballismus","volume":"95","author":"Geoghegan","year":"2002","journal-title":"Ir Med J"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/archneur.1989.00520440044020","article-title":"Hemiballism-hemichorea Clinical and pharmacologic findings in 21 patients","volume":"46","author":"Dewey","year":"1989","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2990.1992.tb00780.x","article-title":"Acute bilateral ballism in a patient with intravascular dissemination of gastric carcinoma","volume":"18","author":"Laing","year":"1992","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib26","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/mds.21100","article-title":"Tetrabenazine for hyperglycemic-induced hemichorea-hemiballismus","volume":"21","author":"Sitburana","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/mds.1095","article-title":"Hemichorea, moya-moya, and ulcerative colitis","volume":"16","author":"Shanahan","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1176\/ajp.118.6.551","article-title":"Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca","volume":"118","author":"Brandrup","year":"1961","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/bmj.1.5698.760-a","article-title":"Tetrabenazine for extra-pyramidal movement disorders","volume":"1","author":"MacCallum","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib30","first-page":"260","article-title":"Metoclopramide induced tardive dyskinesia","volume":"89","author":"Srinivasan","year":"1991","journal-title":"J Indian Med Assoc"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/BF00873549","article-title":"Laryngeal tardive dyskinesia","volume":"242","author":"F\u00e8ve","year":"1995","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1742-1241.2003.tb10446.x","article-title":"Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride","volume":"57","author":"Koch","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mds.870070110","article-title":"Tardive tremor","volume":"7","author":"Stacy","year":"1992","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib34","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/mds.870120533","article-title":"Tardive tremor","volume":"12","author":"Storey","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/mds.870030313","article-title":"Tardive dystonia in patients with Tourette's syndrome","volume":"3","author":"Singh","year":"1988","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1176\/appi.neuropsych.19.4.484-a","article-title":"Olanzapine-induced tardive dystonia successfully treated by tetrabenazine","volume":"19","author":"Rauchverger","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00005053-199310000-00014","article-title":"Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine","volume":"181","author":"Kalian","year":"1993","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib38","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.39.11.1434","article-title":"Tardive oculogyric crises","volume":"39","author":"FitzGerald","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/bmj.4.5726.55","article-title":"Tetrabenazine for Huntington's chorea","volume":"4","author":"Soutar","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib40","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.27.10.942","article-title":"Spinal myoclonus","volume":"27","author":"Hoehn","year":"1977","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib41","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archneur.1986.00520100039012","article-title":"Segmental myoclonus. Clinical and pharmacologic study","volume":"43","author":"Jankovic","year":"1986","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib42","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1136\/bmj.1.6073.1391-a","article-title":"Tetrabenazine in Sydenham's chorea","volume":"1","author":"Hawkes","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mds.870060420","article-title":"What is it? Case 2, 1991: Unusual tremor, myoclonus, and a limping gait","volume":"6","author":"Vecht","year":"1991","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870080123","article-title":"Generalized chorea induced by nonketotic hyperglycemia","volume":"8","author":"Linazasoro","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib45","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.20585","article-title":"Management of the extrapyramidal syndrome in chronic acquired hepatocerebral degeneration (CAHD)","volume":"20","author":"Papapetropoulos","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib46","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.870100603","article-title":"Involvement of respiratory muscles in adult-onset dystonia: A clinical and electrophysiological study","volume":"10","author":"Lagueny","year":"1995","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF00718027","article-title":"Tetrabenazine in the treatment of senile vocal tics","volume":"235","author":"Vieregge","year":"1987","journal-title":"J Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.pnpbp.2009.03.033","article-title":"Pelvic dyskinesia with an outstanding response to tetrabenazine","volume":"33","author":"Alentorn","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1746-160X-2-47","article-title":"Eating dysfunction associated with oromandibular dystonia: Clinical characteristics and treatment considerations","volume":"2","author":"Papapetropoulos","year":"2006","journal-title":"Head Face Med"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1600-0404.1968.tb05581.x","article-title":"The effect of tetrabenazine in some hyperkinetic syndromes","volume":"44","author":"Pakkenberg","year":"1968","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib51","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.2.5654.422","article-title":"Effect of tetrabenazine on extrapyramidal movement disorders","volume":"2","author":"Dalby","year":"1969","journal-title":"Br Med J"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib52","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(74)92823-2","article-title":"Letter: Tetrabenazine in chorea","volume":"1","author":"Astin","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.5694\/j.1326-5377.1979.tb119426.x","article-title":"Tetrabenazine for involuntary movement disorders","volume":"1","author":"Kingston","year":"1979","journal-title":"Med J Aust"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib54","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ana.410130406","article-title":"Blepharospasm and orofacial-cervical dystonia: Clinical and pharmacological findings in 100 patients","volume":"13","author":"Jankovic","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib55","first-page":"19","article-title":"A therapeutic approach to tardive dyskinesia","volume":"46","author":"Fahn","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/070674378803300104","article-title":"Treatment of tardive dyskinesia: Preliminary report on use of tetrabenazine","volume":"33","author":"Watson","year":"1988","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib57","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib58","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.wnf.0000136892.24629.96","article-title":"Tetrabenazine treatment in movement disorders","volume":"27","author":"Paleacu","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-0404.1970.tb05621.x","article-title":"Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes","volume":"46","author":"Fog","year":"1970","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib61","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.35.2.186","article-title":"Treatment of involuntary movement disorders with tetrabenazine","volume":"35","author":"Swash","year":"1972","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/003693307201701105","article-title":"The suppression of involuntary movements with tetrabenazine","volume":"17","author":"McLellan","year":"1972","journal-title":"Scott Med J"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib64","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/archneur.1974.00490410100014","article-title":"Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both","volume":"31","author":"Pakkenberg","year":"1974","journal-title":"Arch Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib65","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archpsyc.1974.01760180095012","article-title":"Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine","volume":"31","author":"Sweet","year":"1974","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib66","first-page":"114","article-title":"Combined therapy with tetrabenazine and pimozide in Huntington's chorea: Pilot study","volume":"83","author":"McArthur","year":"1976","journal-title":"N Z Med J"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.5694\/j.1326-5377.1976.tb140870.x","article-title":"tetrabenazine in the treatment of Huntington's chorea","volume":"1","author":"Huang","year":"1976","journal-title":"Med J Aust"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib68","first-page":"81","article-title":"tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders","volume":"39","author":"Toglia","year":"1978","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-198212000-00005","article-title":"Alpha methylparatyrosine and tetrabenazine in movement disorders","volume":"5","author":"Lang","year":"1982","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib70","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.34.5.688","article-title":"Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome","volume":"34","author":"Jankovic","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib71","first-page":"267","article-title":"Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents","volume":"37","author":"Fahn","year":"1983","journal-title":"Adv Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib72","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp.47.11.1166","article-title":"The treatment of severe dystonia in children and adults","volume":"47","author":"Marsden","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib73","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/BF00461557","article-title":"Tetrabenazine (Nitoman) therapy of chronic spontaneous oral dyskinesia. A video- and EMG-controlled study","volume":"234","author":"Bartels","year":"1984","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib74","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.870010305","article-title":"Natural history and treatment of tardive dystonia","volume":"1","author":"Kang","year":"1986","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib75","first-page":"415","article-title":"Tardive dystonia","volume":"50","author":"Kang","year":"1988","journal-title":"Adv Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib76","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias","volume":"38","author":"Jankovic","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib77","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/ana.410230507","article-title":"Lesch-Nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters","volume":"23","author":"Jankovic","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib78","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1212\/WNL.43.5.937","article-title":"Tardive stereotypy and other movement disorders in tardive dyskinesias","volume":"43","author":"Stacy","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib79","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib80","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","article-title":"Tetrabenazine treatment for Huntington's disease-associated chorea","volume":"25","author":"Ondo","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","article-title":"Shortterm effects of tetrabenazine on chorea associated with Huntington's disease","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib82","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","article-title":"Tourette's syndrome and role of tetrabenazine: Review and personal experience","volume":"28","author":"Porta","year":"2008","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib83","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","article-title":"The longterm effect of tetrabenazine in the management of Huntington disease","volume":"31","author":"Fasano","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib84","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study","volume":"9","author":"Frank","year":"2009","journal-title":"BMC Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.4.5778.25","article-title":"Persistent phenothiazine dyskinesia treated with tetrabenazine","volume":"4","author":"Godwin-Austen","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib86","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.5694\/j.1326-5377.1972.tb103717.x","article-title":"tetrabenazine in the treatment of extrapyramidal dyskinesias","volume":"2","author":"Gilligan","year":"1972","journal-title":"Med J Aust"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib87","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","article-title":"Tetrabenazine and movement disorders","volume":"31","author":"Asher","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study","volume":"11","author":"Jankovic","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib89","first-page":"277","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"37","author":"Jankovic","year":"1983","journal-title":"Adv Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib90","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","article-title":"Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine","volume":"24","author":"Brusa","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib91","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib92","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WNF.0b013e3180ca77ea","article-title":"A study of chorea after tetrabenazine withdrawal in patients with Huntington disease","volume":"31","author":"Frank","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib94","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.WNF.0000228369.25593.35","article-title":"Is history of depression a contraindication to treatment with tetrabenazine?","volume":"29","author":"Kenney","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib95","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/1531-8257(199901)14:1<158::AID-MDS1028>3.0.CO;2-Q","article-title":"Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism","volume":"14","author":"Giladi","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib96","doi-asserted-by":"crossref","first-page":"C3109","DOI":"10.1136\/bmj.c3109","article-title":"Huntington's disease","volume":"340","author":"Novak","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib97","first-page":"1139","article-title":"Prevention, recognition, and management of serotonin syndrome","volume":"81","author":"Ables","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib98","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mds.870120219","article-title":"A case of tetrabenazineinduced neuroleptic malignant syndrome after prolonged treatment","volume":"12","author":"Petzinger","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870110118","article-title":"Tetrabenazine as a cause of neuroleptic malignant syndrome","volume":"11","author":"Ossemann","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mds.870090122","article-title":"Bilateral akinesia in drug-induced parkinsonism after a subthalamic lesion","volume":"9","author":"Kulisevsky","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002826-199202000-00009","article-title":"Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease","volume":"15","author":"Mateo","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib102","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/070674378603100916","article-title":"Iatrogenic parkinsonism in Huntington's chorea","volume":"31","author":"Moss","year":"1986","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib103","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.31.8.1022","article-title":"Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease","volume":"31","author":"Burke","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib104","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/070674370204700716","article-title":"Catastrophic reactions induced by tetrabenazine","volume":"47","author":"Bruneau","year":"2002","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib105","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/jnnp.67.4.550","article-title":"Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition","volume":"67","author":"Schreiber","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib106","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s001340050583","article-title":"Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia","volume":"24","author":"Stevens","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib107","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.410170217","article-title":"Tetrabenazine induces acute dystonic reactions","volume":"17","author":"Burke","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0404.1983.tb04816.x","article-title":"Tolerance of tetrabenazine during long-term treatment","volume":"68","author":"Mikkelsen","year":"1983","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib109","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","volume":"3","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjopharm.2010.08.006_bib110","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S1474-4422(09)70183-8","article-title":"Treatment of hyperkinetic movement disorders","volume":"8","author":"Jankovic","year":"2009","journal-title":"Lancet Neurol"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154359461000070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154359461000070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T02:01:47Z","timestamp":1740535307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154359461000070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S154359461000070X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2010.08.006","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}